Stem Cell Therapy for Knees: What the Research Shows
At a Glance
- Stem cell therapy for knees is the most researched musculoskeletal application of regenerative medicine, with multiple randomized controlled trials showing improvements in pain and function.
- The best candidates have moderate knee osteoarthritis (Kellgren-Lawrence grade 2-3) with some cartilage still remaining – not bone-on-bone.
- Common cell sources include bone marrow aspirate concentrate (BMAC), adipose-derived stromal vascular fraction (SVF), and umbilical cord products.
- Improvement typically appears at 3 to 6 months and may last 1 to 5 years, though results vary significantly between patients.
- Cost ranges from $5,000 to $15,000 per knee, and the treatment is almost never covered by insurance.
- Honest reality: stem cell therapy may slow degeneration and reduce symptoms rather than fully reverse damage or grow new cartilage.
Knee osteoarthritis affects more than 32 million adults in the United States alone, and for many of them, the treatment options feel limited: physical therapy, anti-inflammatory medications, cortisone injections that wear off faster each time, and eventually the prospect of knee replacement surgery. Stem cell therapy has emerged as a potential middle ground – a biological treatment that aims to repair and protect cartilage rather than simply masking symptoms.
But does it actually work? How strong is the evidence? And who is – and is not – a good candidate? This article cuts through the marketing to give you an honest, research-based picture of where stem cell therapy for knees stands today.
Types of Stem Cell Therapy Used for Knees
Not all stem cell treatments are created equal. The cell source matters enormously for both outcomes and regulatory status. Here are the three main categories:
Bone Marrow Aspirate Concentrate (BMAC)
BMAC is the gold standard for autologous (your own cells) stem cell therapy. A needle is inserted into the iliac crest of the hip bone under local anesthesia, and bone marrow is aspirated. The sample is then centrifuged to concentrate the mesenchymal stem cells (MSCs), along with growth factors, cytokines, and other regenerative components.
BMAC typically yields 2,000 to 6,000 MSCs per milliliter of concentrate. While this is a relatively small number of stem cells, they are supported by the full biological milieu of your bone marrow – including hematopoietic stem cells, platelets, and anti-inflammatory signaling molecules.
Adipose-Derived Stromal Vascular Fraction (SVF)
SVF is obtained through a mini-liposuction procedure, usually from the abdomen or flanks. Fat tissue is a rich source of MSCs – yielding roughly 500 to 1,000 times more stem cells per gram than bone marrow. After harvesting, the fat is processed (enzymatically or mechanically) to isolate the stromal vascular fraction, which contains MSCs, endothelial cells, and pericytes.
The higher cell count is appealing, but SVF processing is more regulated by the FDA. Enzymatic digestion of fat tissue is considered “more than minimal manipulation,” which puts many SVF preparations in a regulatory gray area.
Umbilical Cord and Birth Tissue Products
These products – including Wharton’s jelly, amniotic membrane, and cord blood derivatives – are widely marketed as stem cell therapies. However, most commercially available products in this category contain few or no viable, living stem cells after processing and sterilization. They do contain growth factors, hyaluronic acid, and extracellular matrix proteins that may have therapeutic value, but calling them “stem cell therapy” is often misleading.
Ask the Right Questions
Before committing to any stem cell knee treatment, ask your provider: (1) What is the cell source – autologous or donor? (2) What is the expected cell count and viability? (3) Is the processing method FDA-compliant? (4) Can they provide published evidence for their specific protocol? A provider who cannot answer these questions clearly is a provider to avoid.
What the Research Shows: Study Results Summary
The evidence for stem cell therapy in knee osteoarthritis has grown substantially over the past decade. Here is a summary of key studies:
| Study | Cell Source | Patients | OA Grade | Key Findings | Follow-Up |
|---|---|---|---|---|---|
| Shapiro et al. (2017) | BMAC | 25 | KL 2-3 | Significant pain and function improvement vs. saline at 6 months; no MRI cartilage change | 12 months |
| Pers et al. (2016) | Adipose SVF | 18 | KL 2-4 | Low-dose group showed best pain improvement; well tolerated | 6 months |
| Lamo-Espinosa et al. (2020) | BMAC | 30 | KL 2-4 | Significant WOMAC improvement at 12 months; reduced cartilage loss on MRI | 4 years |
| Freitag et al. (2019) | Adipose MSCs (expanded) | 30 | KL 2-3 | Significant pain reduction and MRI-confirmed cartilage preservation at 12 months | 12 months |
| Hernigou et al. (2020) | BMAC | 140 | KL 3-4 | 75% of patients avoided knee replacement at 15-year follow-up vs. 30% in control group | 15 years |
| Kim et al. (2015) | Adipose SVF | 18 | KL 3-4 | Improved WOMAC and VAS scores; arthroscopic evidence of cartilage repair in some patients | 24 months |
The overall pattern: stem cell therapy consistently shows improvements in pain and function for mild-to-moderate knee OA. Evidence for actual cartilage regeneration is more mixed – some studies show cartilage preservation on MRI, but “growing new cartilage” remains the exception rather than the rule. The most impressive long-term data (Hernigou) suggests stem cells may significantly delay the need for knee replacement.
Who Is the Best Candidate?
Patient selection is arguably the most important factor in stem cell therapy outcomes. Here is who tends to do well – and who does not:
Ideal Candidates
- Kellgren-Lawrence grade 2-3 osteoarthritis – moderate joint space narrowing with some cartilage still present
- Age under 70 (though older patients can still benefit)
- BMI under 35 (excess weight accelerates joint degeneration and may reduce treatment efficacy)
- Failed conservative treatment (physical therapy, NSAIDs, corticosteroid or hyaluronic acid injections)
- Motivated to follow post-procedure rehabilitation protocols
- Want to delay or potentially avoid knee replacement surgery
Not Ideal Candidates
- Kellgren-Lawrence grade 4 (bone-on-bone) – there is very little cartilage remaining for stem cells to protect or build upon
- Severe varus or valgus malalignment (knock-kneed or bow-legged deformity) – this creates uneven mechanical stress that overwhelms any biological benefit
- Active joint infection or systemic inflammatory conditions that are poorly controlled
- Patients expecting a complete cure or full cartilage restoration – expectations must be realistic
The Procedure: What to Expect
Understanding what happens during and after the procedure helps reduce anxiety and set expectations.
Before the Procedure
- Stop anti-inflammatory medications (NSAIDs like ibuprofen) at least 1 week before – they can interfere with the healing response
- Get an up-to-date MRI so your provider can assess cartilage status and plan the injection
- Some providers recommend a “pre-habilitation” program of physical therapy to optimize the joint environment
Day of the Procedure
- Harvesting (30-60 minutes): For BMAC, bone marrow is aspirated from the posterior iliac crest under local anesthesia and sedation. For SVF, a small liposuction is performed under local anesthesia. Both are outpatient procedures.
- Processing (20-40 minutes): The harvested material is centrifuged and concentrated in the clinic’s lab or a point-of-care processing system.
- Injection (15-20 minutes): The concentrated stem cell preparation is injected into the knee joint under ultrasound or fluoroscopic guidance to ensure precise placement.
Total time in the clinic: approximately 2 to 3 hours. You will go home the same day.
Recovery and Rehabilitation
- Days 1-3: Mild to moderate soreness and swelling at the injection site and the harvest site (hip or abdomen). Use ice and acetaminophen (not ibuprofen).
- Weeks 1-2: Gentle range of motion and walking are encouraged. Avoid prolonged standing or strenuous activity.
- Weeks 2-6: Gradually increase activity. Low-impact exercise (swimming, cycling, elliptical) is typically cleared by week 3-4. Avoid running, jumping, and heavy lifting.
- Months 2-6: Progressive return to full activity. This is when most patients begin noticing meaningful improvement.
Patience Is Part of the Protocol
One of the most common mistakes patients make is judging the treatment too early. Stem cell therapy is not like a cortisone injection that provides immediate (if temporary) relief. The biological repair process takes months. Most providers recommend waiting at least 6 months before assessing whether the treatment “worked.” Early discouragement at the 4-week mark is normal – and premature.
Cost and Financial Considerations
Stem cell therapy for knees is a significant financial investment:
- BMAC procedure: $5,000 to $10,000 per knee
- SVF procedure: $6,000 to $12,000 per knee
- Combined protocols (stem cells + PRP boosters): $8,000 to $15,000 per knee
- Bilateral (both knees): Many providers offer a discount, typically $8,000 to $20,000 total
These costs are almost never covered by insurance, as stem cell therapy for osteoarthritis remains investigational in the eyes of most insurers. Some clinics offer financing plans with monthly payments.
When evaluating cost, consider the alternative: total knee replacement costs $30,000 to $50,000+ (though largely covered by insurance), requires significant downtime, and carries surgical risks. If stem cell therapy can delay knee replacement by 5 to 10 years – as some long-term data suggests – the out-of-pocket investment may be worthwhile for the right patient.
Honest Limitations: What Stem Cells Cannot Do for Your Knee
Responsible providers are transparent about what stem cell therapy can and cannot accomplish:
- It does not grow a new layer of cartilage in most patients. While some studies show cartilage preservation and occasional repair on MRI, the primary benefit is pain reduction and functional improvement – not structural restoration.
- It does not cure osteoarthritis. OA is a progressive condition. Stem cell therapy may slow the progression and reduce symptoms, but it does not reverse the underlying disease process.
- Results are variable. Some patients experience dramatic improvement; others see modest or no benefit. We cannot yet predict with certainty who will respond well.
- It may need to be repeated. Benefits typically last 1 to 5 years, after which a repeat treatment or alternative approach may be needed.
None of this means stem cell therapy is not worth considering – it means going in with realistic expectations is essential for patient satisfaction.
Frequently Asked Questions
How long does stem cell therapy for knees last?
Most patients experience meaningful improvement for 1 to 5 years, with some studies reporting benefit extending beyond 5 years. The duration depends on factors including the severity of OA at the time of treatment, the cell source and count, patient age and weight, and adherence to post-procedure rehabilitation. Some patients opt for repeat treatments every 2 to 3 years to maintain results.
Is stem cell therapy for knees FDA-approved?
No. The FDA has not approved any stem cell therapy specifically for knee osteoarthritis. However, autologous BMAC (using your own bone marrow concentrate) is generally considered compliant with FDA regulations when it involves “minimal manipulation” and “homologous use.” The regulatory field is more complex for SVF and birth tissue products. The treatment is legal but considered investigational.
Can I walk after stem cell knee injection?
Yes. Most patients can walk with mild discomfort immediately after the injection. The harvest site (hip or abdomen) may be sorer than the knee itself for the first few days. You should plan to take it easy for 2 to 3 days and avoid impact activities for 4 to 6 weeks, but normal walking is encouraged from day one.
What is the success rate of stem cell therapy for knees?
Published studies report that 60% to 80% of appropriately selected patients (KL grade 2-3) experience clinically meaningful improvement in pain and function. Success rates are lower for more advanced OA (KL grade 4). “Success” in most studies is defined as at least a 50% improvement in pain scores – not complete elimination of symptoms. About 20% to 30% of patients report minimal or no benefit.
Related Reading
This article is part of our full guide to regenerative medicine. For a broader overview of stem cell therapy – including applications beyond the knee, how to evaluate providers, and the latest research – visit our pillar guide: Stem Cell Therapy: The Complete Patient Guide.
Considering alternatives? Read our comparison of PRP vs Stem Cell Therapy: Which Is Right for You? to understand how these two regenerative treatments compare.
